HC Wainwright Forecasts Increased Earnings for Cytosorbents

Cytosorbents Co. (NASDAQ:CTSO - Free Report) - Equities researchers at HC Wainwright boosted their FY2025 earnings estimates for shares of Cytosorbents in a note issued to investors on Thursday, May 15th. HC Wainwright analyst S. Lee now anticipates that the medical research company will post earnings per share of ($0.19) for the year, up from their previous estimate of ($0.24). HC Wainwright has a "Neutral" rating and a $1.00 price objective on the stock. The consensus estimate for Cytosorbents' current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Cytosorbents' Q4 2025 earnings at ($0.06) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at ($0.14) EPS, FY2028 earnings at ($0.10) EPS and FY2029 earnings at ($0.09) EPS.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The medical research company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.02. The firm had revenue of $8.73 million during the quarter, compared to analysts' expectations of $9.01 million. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%.

CTSO has been the topic of several other research reports. Wall Street Zen assumed coverage on shares of Cytosorbents in a report on Wednesday. They set a "hold" rating on the stock. D. Boral Capital restated a "buy" rating and issued a $10.00 target price on shares of Cytosorbents in a research note on Thursday, May 15th.

Cytosorbents Trading Down 0.5%

Cytosorbents stock traded down $0.00 during trading on Monday, reaching $0.85. The company had a trading volume of 52,325 shares, compared to its average volume of 146,513. Cytosorbents has a 12-month low of $0.70 and a 12-month high of $1.61. The stock's 50 day moving average price is $0.97 and its two-hundred day moving average price is $0.99. The firm has a market capitalization of $52.91 million, a price-to-earnings ratio of -2.35 and a beta of 1.17. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97.

Hedge Funds Weigh In On Cytosorbents

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CTSO. Skylands Capital LLC raised its holdings in shares of Cytosorbents by 1.0% during the 4th quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company's stock valued at $2,531,000 after purchasing an additional 26,195 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Cytosorbents during the 4th quarter worth about $99,000. Renaissance Technologies LLC increased its stake in Cytosorbents by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company's stock valued at $80,000 after acquiring an additional 8,400 shares during the period. Avenir Corp increased its stake in Cytosorbents by 4.0% in the fourth quarter. Avenir Corp now owns 3,093,946 shares of the medical research company's stock valued at $2,815,000 after acquiring an additional 118,387 shares during the period. Finally, Northern Trust Corp increased its stake in Cytosorbents by 22.3% in the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock valued at $83,000 after acquiring an additional 16,701 shares during the period. Institutional investors and hedge funds own 32.87% of the company's stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.